Metronomic chemotherapy for triple negative breast cancer?

Por Di Desidero, Teresa, Kerbel, Robert S., Bocci, Guido
Publicado no Aging (Albany NY) (2016)

Potent efficacy of metronomic topotecan and pazopanib combination therapy in preclinical models of primary or late stage metastatic triple-negative breast cancer

Por Di Desidero, Teresa, Xu, Ping, Man, Shan, Bocci, Guido, Kerbel, Robert S.
Publicado no Oncotarget (2015)

Metronomic Ceramide Analogs Inhibit Angiogenesis in Pancreatic Cancer through Up-regulation of Caveolin-1 and Thrombospondin-1 and Down-regulation of Cyclin D1

Por Guido Bocci, Anna Fioravanti, Paola Orlandi, Teresa Di Desidero, Gianfranco Natale, Giovanni Fanelli, Paolo Viacava, Antonio Giuseppe^Naccarato, Giulio Francia, Romano Danesi
Publicado em 2012-09-01

Metronomic Ceramide Analogs Inhibit Angiogenesis in Pancreatic Cancer through Up-regulation of Caveolin-1 and Thrombospondin-1 and Down-regulation of Cyclin D1

Por Bocci, Guido, Fioravanti, Anna, Orlandi, Paola, Di Desidero, Teresa, Natale, Gianfranco, Fanelli, Giovanni, Viacava, Paolo, Naccarato, Antonio Giuseppe, Francia, Giulio, Danesi, Romano
Publicado em 2012

Irinotecan Synergistically Enhances the Antiproliferative and Proapoptotic Effects of Axitinib In Vitro and Improves Its Anticancer Activity In Vivo

Por Canu, Bastianina, Fioravanti, Anna, Orlandi, Paola, Di Desidero, Teresa, Alì, Greta, Fontanini, Gabriella, Di Paolo, Antonello, Del Tacca, Mario, Danesi, Romano, Bocci, Guido
Publicado em 2011

The rs2071559 AA VEGFR-2 Genotype Frequency Is Significantly Lower in Neovascular Age-Related Macular Degeneration Patients

Por Lazzeri, Stefano, Orlandi, Paola, Figus, Michele, Fioravanti, Anna, Cascio, Elisa, Di Desidero, Teresa, Agosta, Elisa, Canu, Bastianina, Sartini, Maria Sole, Danesi, Romano, Nardi, Marco, Bocci, Guido
Publicado em 2012

VEGF-A polymorphisms predict progression-free survival among advanced castration-resistant prostate cancer patients treated with metronomic cyclophosphamide

Por Orlandi, P, Fontana, A, Fioravanti, A, Di Desidero, T, Galli, L, Derosa, L, Canu, B, Marconcini, R, Biasco, E, Solini, A, Francia, G, Danesi, R, Falcone, A, Bocci, G
Publicado em 2013

Pharmacodynamic and pharmacogenetic angiogenesis-related markers of first-line FOLFOXIRI plus bevacizumab schedule in metastatic colorectal cancer

Por Loupakis, F, Cremolini, C, Fioravanti, A, Orlandi, P, Salvatore, L, Masi, G, Di Desidero, T, Canu, B, Schirripa, M, Frumento, P, Di Paolo, A, Danesi, R, Falcone, A, Bocci, G
Publicado em 2011

Impact of CTLA-4 blockade in conjunction with metronomic chemotherapy on preclinical breast cancer growth

Por Parra, Karla, Valenzuela, Paloma, Lerma, Natzidielly, Gallegos, Alejandra, Reza, Luis C, Rodriguez, Georgialina, Emmenegger, Urban, Di Desidero, Teresa, Bocci, Guido, Felder, Mitchell S, Manciu, Marian, Kirken, Robert A, Francia, Giulio
Publicado no Br J Cancer (2017)

Genetic interaction of P2X(7) receptor and VEGFR-2 polymorphisms identifies a favorable prognostic profile in prostate cancer patients

Por Solini, Anna, Simeon, Vittorio, Derosa, Lisa, Orlandi, Paola, Rossi, Chiara, Fontana, Andrea, Galli, Luca, Di Desidero, Teresa, Fioravanti, Anna, Lucchesi, Sara, Coltelli, Luigi, Ginocchi, Laura, Allegrini, Giacomo, Danesi, Romano, Falcone, Alfredo, Bocci, Guido
Publicado no Oncotarget (2015)

Clinical, pharmacokinetic and pharmacodynamic evaluations of metronomic UFT and cyclophosphamide plus celecoxib in patients with advanced refractory gastrointestinal cancers

Por Allegrini, Giacomo, Di Desidero, Teresa, Barletta, Maria Teresa, Fioravanti, Anna, Orlandi, Paola, Canu, Bastianina, Chericoni, Silvio, Loupakis, Fotios, Di Paolo, Antonello, Masi, Gianluca, Fontana, Andrea, Lucchesi, Sara, Arrighi, Giada, Giusiani, Mario, Ciarlo, Andrea, Brandi, Giovanni, Danesi, Romano, Kerbel, Robert S., Falcone, Alfredo, Bocci, Guido
Publicado em 2012